Exploratory research of predictive factors in randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab. [SUBSTUDY OF 700223465]

Trial Profile

Exploratory research of predictive factors in randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab. [SUBSTUDY OF 700223465]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel; Steroid receptor modulators
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CAPTURE-TR
  • Most Recent Events

    • 21 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top